Skip to content

Arrowhead Research ARWR Stock-Based Comp

Stock-Based Comp at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$43.28M+45.6%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$33.24M+28.4%
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
$34.02M+62.5%
AbbVie logo
AbbVieABBV
$444M+8.3%
Revvity logo
RevvityRVTY
$8.72M+12.7%
ALN
Alnylam PharmaceuticalsALNY

Segments

By segment

See full
Operating Segment$8.37M+2.9%

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$11.52B+402%
Enterprise value$11.44B+418%
P/S18.5×+14.3×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arrowhead Research's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arrowhead Research's stock-based comp?
Arrowhead Research (ARWR) reported stock-based comp of $16.67M in Q1 2026.
How has Arrowhead Research's stock-based comp changed year-over-year?
Arrowhead Research's stock-based comp increased by 4.0% year-over-year, from $16.03M to $16.67M.
What is the long-term trend for Arrowhead Research's stock-based comp?
Over 4 years (2021 to 2025), Arrowhead Research's stock-based comp has grown at a -4.7% compound annual growth rate (CAGR), from $76.67M to $63.37M.
What does stock-based comp mean?
The non-cash cost of paying employees with company stock instead of cash.
How do you interpret stock-based comp?
High levels may indicate significant dilution for shareholders, while low levels suggest conservative equity management.
How does stock-based comp compare across companies?
Common in high-growth biotech and tech sectors as a tool for talent retention.